IMED INFINITY MEDICAL-LIMITED PARTNERSHIP Financials Imed Infinity Medical-Limited Partnership
Equities
IMED
IL0011712309
Investment Holding Companies
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84 ILa | +11.85% |
|
+12.45% | -26.44% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 12.57 | 4.165 | 1.637 | 1.276 |
| Enterprise Value (EV) 1 | 4.596 | -0.0875 | -0.5693 | -0.2712 |
| P/E ratio | - | -5.43 x | -1.62 x | -0.72 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 55,527,311 x | 8,183,330 x | -1,354,327 x |
| EV / Revenue | - | -1,166,022 x | -2,846,670 x | 287,923 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | 133,285 x | 792,117 x | 305,690 x |
| FCF Yield | - | 0% | 0% | 0% |
| Price to Book | 1.08 x | 0.38 x | 0.17 x | 0.16 x |
| Nbr of stocks (in thousands) | 4,035 | 4,035 | 4,035 | 4,035 |
| Reference price 2 | 3.115 | 1.032 | 0.4056 | 0.3162 |
| Announcement Date | 2/24/21 | 3/23/22 | 3/30/23 | 3/31/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | 0.075 | 0.2 | -0.942 |
| EBITDA | - | - | - | - |
| EBIT 1 | -0.136 | -0.893 | -0.615 | -1.733 |
| Operating Margin | - | -1,190.67% | -307.5% | 183.97% |
| Earnings before Tax (EBT) 1 | -0.136 | -0.766 | -1.006 | -1.77 |
| Net income 1 | -0.136 | -0.766 | -1.006 | -1.77 |
| Net margin | - | -1,021.33% | -503% | 187.9% |
| EPS | - | -0.1900 | -0.2500 | -0.4400 |
| Free Cash Flow | - | -0.6561 | -0.7188 | -0.8872 |
| FCF margin | - | -874.83% | -359.38% | 94.19% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/24/21 | 3/23/22 | 3/30/23 | 3/31/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 7.97 | 4.25 | 2.21 | 1.55 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -0.66 | -0.72 | -0.89 |
| ROE (net income / shareholders' equity) | - | -6.81% | -9.69% | -19.7% |
| ROA (Net income/ Total Assets) | - | -4.9% | -3.65% | -11.9% |
| Assets 1 | - | 15.64 | 27.59 | 14.93 |
| Book Value Per Share 2 | 2.880 | 2.700 | 2.450 | 2.010 |
| Cash Flow per Share 2 | 1.970 | 1.050 | 0.5500 | 0.3800 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 2/24/21 | 3/23/22 | 3/30/23 | 3/31/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.44% | 816K | |
| +18.27% | 77.36B | |
| +65.66% | 18.24B | |
| +4.96% | 16.24B | |
| +7.39% | 14.06B | |
| +0.42% | 12.58B | |
| +7.38% | 11.87B | |
| +6.57% | 10.99B | |
| +33.84% | 10.26B | |
| +0.18% | 9.91B |
- Stock Market
- Equities
- IMED Stock
- Financials Imed Infinity Medical-Limited Partnership